Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Hematological Malignancies

NCT03128359 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03128359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03128359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Hematological Malignancies
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 30, 2017
Completion date
September 15, 2021
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myelogenous leukemia, bcr-abl1 positive, diffuse large b-cell lymphoma, follicular lymphoma, graft versus host disease, hodgkin lymphoma, mantle cell lymphoma, marginal zone lymphoma, myelodysplastic syndrome, myeloproliferative neoplasm, recurrent acute myeloid leukemia with myelodysplasia-related changes, recurrent plasma cell myeloma, refractory plasma cell myeloma, secondary myelodysplastic syndrome